ERBB2 and breast cancer: These data are consistent with previous reports from neoadjuvant breast cancer studies of HER2-targeted therapy [16, 24, 25, 27, 37, 38] and recently reported validation results from the HER2DX assay, which integrates HER2 subtype information, immune information, and ERBB2 levels into a single score [39].